Symphogen A/s

Genentech, Inc.

Les Laboratoires Servier

Genentench, Inc.

Klaus Koefoed

Mikkel Wandahl Pedersen

Michael Kragh

Peter Sejer Andersen

Magnus Strandh

Thomas Bouquin

John A Flygare

Thomas Pillow

Richard L Vandlen

Sanjeev Mariathasan

Leanna Staben

Eric J Brown

John Hiroshi Morisaki

Helle Jane Jacobsen

Sophie M Lehar

Gunther Roland Galler

Monika Gad

Wouter Hazenbos

Johan Lantto

Ivan David Horak

Thomas Tuxen Poulsen

Michael Monrad Grandal

Torben Gjetting

Lucilla Steinaa

Allan Jensen

Per-Johan Meijer

Martine Darwish

Byoung Chul Lee

Charles Pyke

Robert Carlsson

Lars Søgaard Nielsen

Lars Soegaard Nielsen

Trine Lindsted

Ida Kjær

Ida Kjaer

Lars Sogaard Nielsen

Vikram Kjoller Bhatia

Paolo Conrotto

Karsten Wessel Eriksen

Thomas H Pillow

Eric Brown

Byoung-Chul Lee

Soegaard Nielsen

This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.

Anti-PD-1 antibodies and compositions

This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Anti-TIM-3 antibodies and compositions

This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

Anti-wall teichoic antibodies and conjugates

The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.

Anti-MET antibodies and compositions

The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

Methods for treating cancer by administering humanized pan-HER antibody compositions

Humanized pan-HER antibody compositions

The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.

Anti-HER3 antibodies and compositions

The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.

Recombinant anti-epidermal growth factor receptor antibody compositions

Growing community of inventors

København S, Denmark

Klaus Koefoed